atients with breast cancer often exhibit no evidence of disseminated disease at initial diagnosis, yet ~20% of patients ultimately relapse 1 . Metastatic dissemination often begins at early stages 2, 3 , yielding many latent micrometastases. By some estimates, less than 0.02% of those disseminated tumour cells will form secondary tumours, indicating that successful metastatic colonization is rare 4-6 and ascribed to only specialized minority cancer cells, termed MICs 7 . The seemingly simultaneous emergence of clinically detectable metastases has led to the notion that reactivation of secondary lesions from dormancy is triggered systemically 8, 9 . Preclinical modelling has revealed that primary tumours influence metastasis by modulating both systemic and secondary tumour microenvironments before and after dissemination [10] [11] [12] [13] [14] [15] . The role of the immune system during these processes is particularly complex 16 . Little is known about the impact of the immune system on MIC colonization or the context in which primary tumour-driven pathophysiology will prove to be pro-or antimetastatic.
These authors contributed equally to this work: Christine L. Chaffer, Sandra S. McAllister. *e-mail: c.chaffer@garvan.org.au; smcallister1@bwh.harvard.edu P atients with breast cancer often exhibit no evidence of disseminated disease at initial diagnosis, yet ~20% of patients ultimately relapse 1 . Metastatic dissemination often begins at early stages 2, 3 , yielding many latent micrometastases. By some estimates, less than 0.02% of those disseminated tumour cells will form secondary tumours, indicating that successful metastatic colonization is rare [4] [5] [6] and ascribed to only specialized minority cancer cells, termed MICs 7 . The seemingly simultaneous emergence of clinically detectable metastases has led to the notion that reactivation of secondary lesions from dormancy is triggered systemically 8, 9 . Preclinical modelling has revealed that primary tumours influence metastasis by modulating both systemic and secondary tumour microenvironments before and after dissemination [10] [11] [12] [13] [14] [15] . The role of the immune system during these processes is particularly complex 16 . Little is known about the impact of the immune system on MIC colonization or the context in which primary tumour-driven pathophysiology will prove to be pro-or antimetastatic.
Successful metastatic colonization is also largely dependent on the inherent biology of the tumour cell. Cellular plasticity is a fundamental component of several leading metastasis models, including co-option of developmental pathways, the epithelialto-mesenchymal transition (EMT) and cancer stem cell models 17 . Once MICs reach a distant tissue, the necessity of cellular plasticity to developing overt metastatic lesions remains to be determined. Clinical and preclinical findings therefore provoke the question of whether the success of disseminated MICs is influenced by overall disease pathophysiology.
Results
Identification of primary tumours that inhibit metastatic colonization. To determine whether primary tumours influence colonization of disseminated MICs, we first employed a polyclonal metastatic mammary carcinoma cell line, Met1, derived from a spontaneous lung metastasis in an FVB/N-Tg(MMTV-PyMT) mouse 18 . Met1 cells or PBS vehicle control were injected orthotopically into FVB mice. After 2 weeks, when primary tumours reached ~100 mm 3 ( Supplementary Fig. 1a ), we synchronized metastasis by injecting the same heterogeneous Met1 population intravenously (Fig.1a) , whereby only the MIC subpopulation should be capable of seeding metastases 19 . Lungs were analysed after a subsequent 2-week period.
In three independent experiments, the control cohort developed overt pulmonary metastases while no macrometastases were observed in mice bearing orthotopic Met1 primary tumours (Fig. 1b,c) . Importantly, orthotopic Met1 primary tumours did not inhibit the development of Met1 secondary tumours that were injected subcutaneously ( Supplementary Fig. 1b ), an injection scheme that does not provide selection pressure for murine MIC (mMIC)
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Articles NATUrE CELL BIOLOgy subpopulations 19 . These results suggested that Met1 primary tumours specifically inhibit growth driven by their MICs and not the bulk, heterogeneous population of tumour cells.
We previously generated a series of single cell-derived clones from the parental Met1 line 20 . To identify a purified population of Met1 mMICs, we tested the metastatic potential of two of . Primary tumour growth kinetics were monitored from day 0; pulmonary metastases were quantified at experimental end points. b,d,f, H&E images of lungs from mice bearing Met1 primary tumours or PBS control. c,e,g, Macrometastases (macro-mets) > 100 µ m quantified from microscopy tissue sections from 4 lung lobes per animal for mMIC metastases in FVB mice (PBS, n = 7 animals; Met1, n = 8 animals) (c), mMIC-MT3 metastases in FVB mice (PBS, n = 9 animals; Met1, n = 10 animals) (e), and mMIC metastases in nude mice (PBS, n = 5 animals; Met1, n = 4 animals) (g). h, Schematic modelling the early stages of hMIC colonization in the presence of a HMLER primary tumour in nude mice (i-k). Matrigel vehicle is the experimental control for primary tumours. HMLER cells (5.0 × 10 5 per mouse) or Matrigel control (100 μ l) were injected subcutaneously (s.c.) into one flank at day 0. Two weeks later, hMIC (2.5 × 10 5 cells per mouse) were injected subcutaneously into the contralateral flank. Growth kinetics were monitored for the duration of the experiment. i, H&E images of hMIC tumours from mice bearing HMLER primary tumours or Matrigel control. j, hMIC tumour growth kinetics in mice bearing Matrigel control (n = 9 animals) or HMLER primary tumours (n = 10 animals). k, Left: hMIC tumours opposite Matrigel (n = 25 images representing 4 tumours) or HMLER primary tumours (n = 25 images representing 6 tumours), stained for mouse panendothelial cell antigen (MECA32). Right: mean vessel number per microscopy field. l, Tumour growth kinetics of hMIC implanted opposite Matrigel control or an HMLER2 primary tumour (n = 10 animals per cohort), per protocol in 1 h. All scale bars, 100 µ m. Source data for c, e, g, j, k and l are provided in Supplementary Table 1. Welch's two-sided t-test (c, e, g and k); Two-way ANOVA followed by Sidak's multiple comparison test (j and l).
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NATUrE CELL BIOLOgy these clones, MT2 and MT3. The MT3 subclone was subsequently defined as a mMIC population due to its enhanced metastatic potential (~90 macrometastases per field; 100% incidence) compared to poorly metastatic MT2 cells (~1 macrometastasis per field; 66.6% incidence) ( Supplementary Fig 1c) . Hence, Met1 primary tumours or control PBS were orthotopically injected into cohorts of FVB mice followed 2 weeks later by intravenous injection of the mMIC-MT3 cells (Fig. 1a) . At the experimental end point, mMIC-MT3 pulmonary metastases were reduced by approximately sixfold in the cohort bearing Met1 primary tumours relative to the control cohort (Fig. 1d,e) .
To test whether adaptive immunity was necessary for inhibiting mMIC pulmonary metastases, we conducted the same experiments in athymic nude mice. After 2 weeks, when primary tumours reached ~200 mm 3 ( Supplementary Fig. 1d ), Met1 cells were injected intravenously (Fig.1a) . Again, Met1 primary tumours significantly inhibited pulmonary metastases (Fig. 1f,g ), indicating that mMIC inhibition was not T cell-dependent.
The results from immunocompromised mice presented us with the opportunity to test human xenografts. Accordingly, we used the polyclonal human mammary carcinoma cell line HMLER, which represents heterogeneous cell populations commonly observed in primary breast cancers. We used a well-characterized clonal MIC subpopulation (hMIC) that had been isolated directly from the HMLER cell line; compared with other HMLER subclones, hMIC is uniquely metastatic 21 . Primary HMLER tumours significantly inhibited the outgrowth of subcutaneous hMIC secondary tumours (Fig. 1h-j) as well as hMIC pulmonary metastases ( Supplementary Fig. 1e ). We also tested highly metastatic MDA-MB-231 human breast cancer cells, which are enriched for hMICs 22 . These MDA-MB-231-MIC secondary tumours were also significantly inhibited by HMLER primary tumours ( Supplementary Fig. 1f-i) .
We ruled out the possibility that the primary tumours inhibited hMIC outgrowth through the release of anti-angiogenic factors 23 . In fact, hMIC-derived tumours from mice bearing primary tumours contained ~2.5-fold more blood vessels per section than the control cohort (Fig. 1k) .
Importantly, we discovered that primary tumours from another HMLER derivative subpopulation, HMLER2 21 , did not inhibit hMIC colonization (Fig. 1l) . This finding suggested that there are properties specific to inhibitory primary tumours. , and Ki67 (brown) and haematoxylin (nuclei; blue) (c,d). e,f, Immunofluorescence for E-cadherin (ECAD; red), large T antigen (LgT; green) to identify hMICs, and DAPI (nuclei; blue), with lung metastases circled in white. g,h, ECAD + cells as the percentage of the total number of LgT + tumour cells (g) or DAPI + cells (h) per microscopy field (ECAD in hMIC tumours, n = 20 images representing 5 tumours per cohort; ECAD in mMIC-MT3 metastasis, n = 52 images representing at least 18 metastases per cohort). i-l, Immunofluorescence images of hMIC tumours after 14 days of growth stained with ECAD (i) and quantified (j) (Matrigel cohort, n = 15 images; HMLER cohort, n = 13 images) or ZEB1 (k) and quantified (l) (Matrigel cohort, n = 13 images; HMLER cohort. n = 16 images); j and l are presented as the percentage of the total number of LgT + hMIC tumour cells. m,n, hMIC tumours after 44 days of growth (per Fig. 1a ). Immunofluorescence images (m) and quantification (n) of ZEB1 staining (red) in hMIC tumours (positive for LgT antigen; green), as a percentage of the total of LgT + cells. DAPI (nuclei; blue). Control, n = 20 independent images representing 3 tumours; HMLER cohort, n = 20 independent images representing 3 tumours. o, ZEB1 (red), LgT + tumour cells (green), and DAPI (nuclei; blue) in hMIC tumours expressing either doxycycline-inducible control (control hMIC) or ZEB1 cDNA (ZEB1 high hMIC). All scale bars, 100 µ m. p, Final mass of hMIC tumours from (o) (Control hMIC, n = 6 tumours; ZEB1 high hMIC, n = 6 tumours). Source data for g, h, j, l, n and p are provided in Supplementary Fig. 1a ). Haematoxylin (nuclei; blue). e,f, Quantification of pulmonary neutrophils from FVB mice (e) and nude mice (f). For FVB mice: control cohort, n = 21 independent images representing 7 lungs; Met1 primary tumour cohort, n = 24 independent images representing 8 lungs. For nude mice: control, n = 15 independent images representing 5 lungs; Met1 primary cohort, n = 12 independent images representing 4 lungs. g,h, Representative immunohistochemistry (g) and corresponding quantification (h) of hMIC tumours that had grown for 44 days opposite Matrigel, HMLER or HMLER2 tumours (per Fig. 1h ). Tissues stained with F4/80 (macrophages; brown); haematoxylin (nuclei; blue). Control, n = 28 independent images representing 7 tumours; HMLER, n = 24 independent images representing 7 tumours; HMLER2, n = 16 independent images representing 4 tumours. i, Schematic of neutrophil depletion experiments using 100 μ g of either anti-Ly6G (a-Ly6G) or IgG control. j, Incidence of pulmonary macrometastases (control IgG2a, n = 4 mice per cohort; anti-Ly6G, n = 8 mice per cohort). k, ECAD + /PyMT + staining in mMIC lung metastases. l, average mMIC lung metastasis size. mMIC opposite control PBS: anti-IgG2a, n = 40 independent images representing 4 mice; anti-Ly6G n = 39 independent images representing 4 mice. mMIC opposite Met1 primary tumour: anti-IgG2a, n = 3 independent images representing 5 mice; anti-Ly6G n = 33 independent images representing 4 mice. Scale bars, 100 µ m. Source data for c, e, f, h, j, k and l are provided in Supplementary 
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These data established several important principles. First, primary tumours that inhibited MIC colonization did not prevent the outgrowth of heterogeneous tumour cell populations composed of MICs and non-MICs, suggesting that MIC-specific properties make them susceptible to growth inhibition. Second, systemic growth inhibition of MICs is not tissue-specific, since primary tumours inhibited the outgrowth of both subcutaneous and pulmonary MICs. Third, primary tumours systemically inhibited MICs independently of an adaptive immune system without affecting MIC vascularization, pointing to innate immune mechanisms. Fourth, not all primary tumours inhibited distant MIC colonization.
MIC proliferation and differentiation are mechanistically linked.
The histopathology of control cohort hMIC tumours was consistent with that of breast ductal adenocarcinomas observed in the clinic (Fig. 2a) . In contrast, cancer cells in hMIC tumours from cohorts bearing primary HMLER tumours appeared mesenchymallike, resembling breast spindle cell carcinomas (Fig. 2a) . Similarly, mMIC-MT3 metastatic foci in primary tumour-bearing mice appeared poorly differentiated (Fig. 2b) . hMIC and mMIC proliferation was significantly reduced in cohorts bearing primary tumours relative to their respective control cohorts (Fig. 2c,d ).
Evidence from multiple groups has indicated that MICs reside in a partial-EMT state 24 . As MICs generate their non-MIC progeny during secondary tumour formation, mesenchymal properties are lost and epithelial phenotypes are reacquired 7, 25 . Our histopathological observations supported the hypothesis that inhibitory primary tumours maintain the MIC mesenchymal state and prevent differentiation into epithelial progeny.
Consistent with MIC traits, both hMICs and mMICs expressed low or undetectable levels of the epithelial marker E-cadherin (ECAD) in vitro at the time of their injection ( Supplementary  Fig. 2a,b) . In vivo, however, MIC-derived metastases and secondary tumours from control cohorts acquired ECAD expression, which was approximately fivefold higher in hMICs and approximately twofold higher in mMICs compared with MICs from primary tumour-bearing mice ( Fig. 2e-h ). Epithelial phenotypic plasticity was also apparent when we visualized cytokeratin and vimentin ( Supplementary Fig. 2c,d ).
We next asked whether the blocks in MIC differentiation and growth inhibition were mechanistically related. We reasoned that these responses should be analysed from size-matched MIC-derived tumour tissues. We therefore used the hMIC model and injected either HMLER cells or Matrigel control subcutaneously into mice; 14 days later, we injected hMICs into the contralateral flanks of the mice in each cohort and harvested tumours 14 days later ( Supplementary Fig. 2e ). At this early time point, hMIC tumours were comparable in size (~50 mm 3 ) between cohorts, although hMIC tissues from the mice with primary tumours had ~62% fewer proliferating tumour cells with no significant differences in numbers of caspase 3-positive cells ( Supplementary Fig. 2e-i) .
We examined these small secondary tumours for ECAD and for the human mesenchymal marker ZEB1 26 , which is highly expressed in hMICs in vitro ( Supplementary Fig. 2b ). In the control cohort (no primary tumour), the vast majority of hMICs acquired ECAD expression, with only ~10% of the cells expressing ZEB1 (Fig. 2i-l) . In striking contrast, hMICs from the mice bearing primary tumours largely maintained ZEB1 expression (~90%), with only a small fraction of tumour cells acquiring ECAD expression (Fig. 2i-l) .
The ZEB1 high phenotype persisted through later end points (Fig. 2m,n) . We therefore tested the effects of locking MICs in a mesenchymal state by creating and injecting hMICs that stably express either ZEB1 (ZEB1 high hMICs) or an empty vector control (control hMICs) ( Supplementary Fig. 2j ). After 6 weeks, the ZEB1 high hMIC tumours were 20-fold smaller than control hMIC tumours and indeed maintained high ZEB1 protein expression (Fig. 2o,p) . Hence, maintaining high ZEB1 expression in hMICs, either in the presence of a primary tumour or by ZEB1 overexpression, severely compromises their tumour-forming ability.
These data demonstrated that proliferation is mechanistically linked to MIC epithelial plasticity, which was critical for robust tumour growth. Specifically, reduced proliferation in the mesenchymal state accounts for the lack of MIC outgrowth when a distantly located primary tumour is present.
Myeloid cells in the metastatic microenvironment prevent MIC differentiation and colonization. A transcriptomic analysis of lung tissues 14 days after control PBS or Met1 primary tumour initiation-the time point at which mMIC metastases typically encounter the lungs ( Supplementary Fig. 3a ,b)-revealed a list of significantly differentially expressed genes (DEGs) that clustered by cohort ( Supplementary Fig. 3c,d ; Supplementary Table 2 ). The MICsuppressive lung environment was defined by functionally enriched gene ontology (GO) terms and pathways involved in leukocyte (myeloid, neutrophil and granulocyte) migration and chemotaxis and diminished for protein-folding responses (Fig. 3a,b) .
In agreement with RNA sequencing (RNA-seq) results, neutrophils were abundant in the lungs and approximately fourfold higher in the circulation of the tumour-bearing cohort than in the tumourfree cohort (Fig. 3c ). Increased neutrophil infiltration persisted throughout disease progression to the 28-day experimental end point ( Fig. 3d ,e and Supplementary Fig. 3e ) and was also apparent in the lungs of nude mice (Fig. 3f ).
Myeloid cells, including macrophages and neutrophils, can confer either pro-or antitumorigenic functions that are governed in tissue-and microenvironment-specific contexts 10, 11, 13, [27] [28] [29] . One particular study reported gene expression signatures of breast cancer metastasis-promoting, immune-suppressive circulating neutrophils ("KEP") 13 . An analysis of the reported KEP and of normal lung neutrophil signatures revealed that the lungs from mice with Met1 primary tumours had a lower KEP:normal ratio (~1.7) compared to the control cohort (ratio of ~2.8) (Supplementary Fig. 3f ). Similarly, leukotrienes expressed by pre-metastatic lung neutrophils to expand the MIC pool in a reported study 11 were not differentially expressed in the lungs of the tumour-bearing cohort (see GSE111157). These results suggested that the neutrophils in lungs of Met1 tumour-bearing mice are entrained differently to those of previously described circulating neutrophils.
Similarly, myeloid cells infiltrated the hMIC tumours from mice bearing inhibitory human primary tumours (HMLER) but not those bearing non-inhibitory primary tumours (HMLER2). In these cases, macrophages were ~4.5-fold more abundant in hMIC secondary tumours from mice with primary HMLER tumours than either Matrigel controls or HMLER2 tumour-bearing mice (Fig.  3g,h ).
To determine whether neutrophils are necessary for inhibiting mMIC lung colonization, we neutralized Ly6G + cells. We selected an optimal anti-Ly6G dose that restored circulating Ly6G + cells to that of the control cohorts, did not affect primary tumour growth and reduced lung neutrophil infiltration ( Supplementary Fig. 3g-l) . We then orthotopically injected PBS control or Met1 cells and after 10 days, animals were randomized into two additional cohorts to receive either anti-Ly6G or control IgG2a every 2 days. mMIC cells were then injected intravenously into all cohorts at day 14, and the dosing regimens were continued (Fig. 3i) .
As expected, pulmonary macrometastases were reduced approximately fourfold in the primary tumour-bearing cohort treated with control IgG2a relative to the control primary tumour-free cohort (Fig. 3j) . However, when the primary tumour-bearing cohort was treated with anti-Ly6G and circulating neutrophils were reduced to that of the control cohort without affecting primary tumour mass ( Supplementary Fig. 3m ,n), metastatic colonization was no longer Articles NATUrE CELL BIOLOgy inhibited (Fig. 3j) . Neutrophil ablation was associated with significantly larger pulmonary metastases that displayed approximately twofold more ECAD expression compared with the control IgG2a cohort ( Fig. 3k,l ; Supplementary Fig. 3o -q). We confirmed that lung neutrophils were maintained at baseline levels while lung monocytes were unaffected at the experimental end point (Supplementary Fig. 3r ).
IL-1β is sufficient to prevent MIC differentiation. We next interrogated candidate DEGs as drivers of MIC suppression. Among the top most-upregulated DEGs in the lungs of mice with primary tumours, we considered pro-inflammatory cytokines common to both neutrophils and macrophages 13, 30, 31 ( Supplementary Fig. 4a ). One of the most highly upregulated DEGs in lungs of primary tumour-bearing mice was IL-1β (Fig. 4a) , which is known to drive ZEB1 expression 32, 33 . IL-1β was significantly more abundant in the lungs of both FVB and nude mice bearing Met1 primary tumours (Fig. 4b,c) , and mMICs did not secrete appreciable levels of IL-1β in culture ( Supplementary Fig. 4b ). We confirmed that murine Met1 cells and derivative clones, MT2 and MT3, expressed IL-1 receptor (IL-1R) and were responsive to IL-1β in a dose-dependent manner ( Supplementary Fig. 4c ).
We also assessed IL-1 expression in hMIC tumours from HMLER-and Matrigel-bearing mice by species-specific quantitative PCR (qPCR). Human IL1B and IL1A expression were not different between cohorts (Fig. 4d) . In fact, hMICs secrete very low levels of IL-1β (< 1 pg ml -1 ) in culture ( Supplementary Fig. 4d ). However, relative to Matrigel control mice, murine Il1b expression was 2.7-fold elevated in hMIC tumours from mice bearing primary tumours; this was accompanied by a 3.4-fold increase in human IL1R1 expression (Fig. 4d) . Indeed, murine IL-1β can efficiently bind and activate human IL-1R1 34 , and IL-1β induces the expression of IL1R1, thereby amplifying IL-1 signalling 35, 36 . Tumour-associated macrophages (positive for both CD11b and F4/80) equivalently infiltrated hMIC tumours from both cohorts at the early time point (Supplementary Fig. 4e ). However, macrophages expressed significantly higher levels of intracellular IL-1β protein per cell in the cohort with primary tumours than those from the control cohort (Fig. 4e) .
We directly tested the effects of IL-1β on MIC plasticity by admixing hMICs with Matrigel containing either IL-1β (hMIC + IL-1β ) or PBS control (hMIC + PBS) (Fig. 4f) . After 2 weeks, the hMIC + IL-1β tumours had significantly fewer ECAD + tumour cells and more ZEB1
+ tumour cells than the hMIC + PBS tumours (Fig. 4g,h ). Importantly, hMIC + IL-1β tumours displayed significantly enhanced macrophage infiltration (Fig. 4i) , demonstrating that a single dose was sufficient to trigger a sustained inflammatory response and maintain the mesenchymal phenotype.
IL-1R1 signalling is necessary for preventing MIC differentiation.
To test whether IL-1R1 signalling is necessary for preventing MIC differentiation, we first generated hMIC cells deficient in IL-1R1 (sh-IL-1R1-hMIC) and scrambled short hairpin RNA (shRNA) control cells (sh-Ctl-hMIC). Only one out of six shRNA constructs provided sufficient suppression of IL-1R1 without significantly affecting cell proliferation ( Supplementary Fig. 5a,b) ; hence, we performed all in vivo experiments with those sh-IL-1R1-hMIC cells only. Cohorts of mice bearing primary HMLER tumours or Matrigel control were injected with sh-IL-1R1-hMIC or sh-CtlhMIC cells and tissues were harvested 2 weeks later (Fig. 5a ). hMIC tissue mass was not significantly different between cohorts at this time point (Supplementary Fig. 5c ).
Echoing earlier results, the sh-Ctl-hMIC tumours from mice with primary tumours had significantly fewer ECAD + cells and more ZEB1
+ cells than those from the Matrigel control cohort (Fig. 5b,c) . In stark contrast, the sh-IL-1R1-hMIC tumours from both cohorts expressed similar levels of ECAD and ZEB1, and the majority of tumour cells from both cohorts were in ZEB1 low ECAD high state (Fig. 5b,c) .
We also treated mMICs in a three-dimensional tumoursphere assay with IL-1β , anakinra (an IL-1R1 antagonist), a combination of IL-1β + anakinra, or vehicle control. IL-1β treatment activated nuclear factor-κ Β (NF-κ Β ) signalling and significantly reduced tumoursphere size, whereas anakinra reduced NF-κ Β activation and increased both tumoursphere size and ECAD protein levels ( Supplementary Fig. 5d,e) .
In addition to dysfunctional adaptive immunity, NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice have an impaired innate immune system, of which defects in IL-1 signalling are a particular feature 37 . Hence, we injected cohorts of NOD/SCID mice with either Matrigel or HMLER primary tumours. After 10 days, circulating monocytes were not significantly different between cohorts (Supplementary Fig. 5f ). At day 14, we then injected either hMICs or hMICs with recombinant IL-1β (hMICs + IL-1β ) as secondary tumours and harvested tissues of equivalent mass after an additional 2 weeks (Fig. 5d,e,  Supplementary Fig. 5g ).
The majority of hMIC tumour cells in the control NOD/SCID mice were ECAD high ZEB1 low ( Fig. 5f,g ). However, unlike nude mice, HMLER primary tumours failed to lock distant hMICs in the ZEB1 + state and these hMIC tumour cells were also ECAD high ZEB1 low ( Fig. 5f,g ). Therefore, ablation of IL-1β -dependent aspects of innate immunity prevented MIC entrapment in the mesenchymalenriched state, even in the presence of a distant primary tumour. Finally, addition of recombinant IL-1β maintained hMICs in a ZEB1 + ECAD low state (Fig. 5f,g ), indicating that hMICs were still capable of responding to IL-1β in NOD/SCID mice.
These observations indicated that the ability of primary tumours to systemically maintain secondary hMIC tumours in the ZEB1
+ ECAD low state critically depended on eliciting systemic inflammation involving IL-1β -secreting innate immune cells and IL-1R pathway activation in the disseminated MICs.
MIC-inhibitory primary tumours elicit a systemic inflammatory response. Our results thus far suggested that MIC-inhibitory primary tumours elicit a systemic pro-inflammatory response. Indeed, myeloid cells infiltrated the Met1 and HMLER primary tumours but not the HMLER2 primary tumours that did not suppress distant hMIC outgrowth ( Fig. 6a,b; Supplementary Fig. 6a ). Circulating neutrophils were significantly increased 10 days after disease initiation (that is, before mMIC implantation) in the Met1 primary tumour-bearing FVB cohort (Fig. 6c) . Moreover, there was a 10% increase in circulating monocytes in HMLER tumour-bearing nude mice after just 14 days (Fig. 6c,d ).
In the bone marrow of FVB mice, short-term haematopoietic stem cells (ST-HSCs), common myeloid progenitors (CMPs) and granulocyte-monocyte progenitors (GMPs) expanded 28 days after Met1 tumour establishment while production of haematopoietic stem cells (HSCs), long-term HSCs (LT-HSCs), common lymphoid progenitors (CLPs) and megakaryocyte/erythroid progenitors (MEPs) decreased (Fig. 6e) . The shift towards CMPs and GMPs reflected a skewing towards the production of neutrophil and macro phage precursors. Circulating neutrophils were still significantly elevated by the end stage in both FVB and nude mice (Fig. 6f) . Similarly, bone marrow monocytes and their expression of intracellular IL-1β were significantly elevated at end-stage of HMLER primary disease (Fig. 6g) . These results were indicative of a sustained pro-inflammatory response throughout disease progression.
Inhibiting inflammation at the primary tumour site results in distant MIC differentiation and growth. Our results suggested that inhibiting inflammation at the primary tumour site should affect Articles NATUrE CELL BIOLOgy the systemic cascade of events that resulted in MIC suppression at distant sites. Therefore, we analysed the primary tumours for pro-inflammatory factors that we could interrogate.
An expression analysis of Met1 primary tumours relative to control tissues (GSE111157) showed enhancement of gene terms related to inflammation and neutrophil recruitment. Some of these 
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+ cells in hMIC tumours (3 tumours per cohort) opposite Matrigel (n = 18 independent images), HMLER (n = 9 independent images), or hMIC + IL-1β tumours opposite Matrigel (n = 9 independent images) (g). Scale bars, 100 µ m. Source data for c, f and g are provided in Supplementary 
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NATUrE CELL BIOLOgy included IL-1β , lipocalin 2 (LCN2), granulocyte colony stimulating factor (G-CSF), chemokine (C-C motif) ligand 2 (CCL2, also known as monocyte chemoattractant protein 1), and tumour necrosis factor-α (TNF-α ) (Supplementary Fig. 7a) . A cytokine analysis also revealed a number of pro-inflammatory cytokines that were secreted at significantly higher levels (≥ threefold) by the HMLER cells than the non-inhibitory HMLER2 cells, including IL-1α and LCN2 (Fig. 7a) . A number of these same cytokines, including IL-1α , LCN2 and G-CSF, were secreted at significantly higher levels (≥ twofold) by the HMLER cells than hMICs (Supplementary Fig. 7b ).
Our earlier results (Figs. 3-5 ) established that neutrophil neutralization or IL-1R1 suppression within the metastatic niche affects MIC differentiation and colonization; therefore, therapeutic approaches designed to systemically inhibit inflammation would not reveal the necessity or exclusivity of primary tumours in initiating the MIC-inhibitory cascade. Therefore, we sought strategies to inhibit inflammation proximal to the primary tumour. Among the various pro-inflammatory cytokines secreted by primary tumours, IL-1α stood out due to its prominence as a local initiator of systemic inflammatory responses 33 . Importantly, IL-1R activation triggers the induction of some of the pro-inflammatory cytokines that we had observed, including TNF-α 38 , LCN2 39 and CCL2 40, 41 . Indeed, IL-1α was greater than sixfold more abundant in conditioned medium from HMLERs than from hMICs (Fig. 7b) .
To determine whether primary tumour IL-1R1 signalling initiates the pro-inflammatory cascade, we used a recombinant IL-1 receptor antagonist (IL-1Ra) 42 . We implanted Matrigel control, HMLER cells or HMLER cells mixed with IL-1Ra (HMLER + IL-1Ra) into mice and collected blood 13 days later (Fig. 7c) . At this time point, circulating monocytes were 2.4-fold elevated in the primary 
NATUrE CELL BIOLOgy tumour-bearing cohort relative to the Matrigel controls (Fig. 7d) . However, in the cohort bearing HMLER + IL-1Ra tumours, circulating monocytes were reduced to that of the control cohort (Fig. 7d) . Murine inflammatory plasma cytokines that are commonly triggered by IL-1R1 signalling (for example, TNFα , G-CSF and CCL1) were also elevated in mice with HMLER primary tumours but not in the cohort bearing HMLER + IL-1Ra tumours (Supplementary Fig. 7c ).
Having confirmed an IL-1-dependent host inflammatory response at day 13, we initiated hMIC secondary tumours in all 3 cohorts the following day (day 14) and continued the experiment for another 2 weeks (Fig. 7c) . Primary tumour masses were equivalent, yet myeloid infiltration into primary HMLER + IL-1Ra tumours was reduced 6.4-fold compared to HMLER controls (Fig. 7e, Supplementary Fig. 7d-g ). Macrophages were also less abundant in the secondary hMIC tumours from mice bearing the distant HMLER + IL-1Ra primary tumours ( Supplementary  Fig. 7h ). Confirming earlier findings, hMICs from mice bearing primary tumours were predominantly ZEB1 + ECAD low . In contrast, when IL-1R1 signalling was inhibited at the primary tumour site, hMIC secondary tumours acquired the ZEB1 low ECAD high epithelial phenotype (Fig. 7f,g, Supplementary Fig. 7i,j) .
Low IL-1β expression in primary breast cancer correlates with reduced metastasis-free survival. Our studies demonstrated that innate immune cells secreting IL-1β , mobilized by the primary tumour, compromise MIC colonization at secondary sites by preventing their differentiation into epithelial progeny, which is essential for forming actively growing tumours (Fig. 8a) . Given that this cascade of events depends on the continued presence of the primary tumour, clinical validation relied on careful selection of appropriate patient populations. Indeed, hMIC-derived metastases were not inhibited if the IL-1β -dependent inflammatory cascade was instigated after MIC dissemination and growth initiation (Fig. 8b,c) . hMIC tumours that were < 2 mm (low mitotic index) at the time of HMLER implantation were significantly suppressed. However, if hMIC tumours had already entered an active growth phase (> 2 mm) at the time of primary tumour implantation, MIC-derived tumours sustained continued growth (Fig. 8c) . These data provided preliminary indication that HMLER tumours do not cause regression of robustly growing hMIC tumours but instead exert their inhibitory effects at early stages of secondary tumour establishment when MICs are still in the ZEB1 + state. We therefore compared primary tumour IL-1β expression in breast cancer patients with lymph node-positive (LN + ) and LN-negative (LN -) disease by retrospective gene set analyses using a database of Affymetrix microarray profiles 43 . Among 508 patients with LN -disease, IL-1β expression did not stratify for overall survival (Fig. 8d) . However, among 215 patients with LN + breast cancer, those with high IL-1β expression had improved overall survival relative to those with low IL-1β expression (Fig. 8e) . Interestingly, patients whose primary tumours expressed high IL-1β had improved outcomes (distant metastasis-free survival) when we interrogated the entire cohort of 1,379 patients ( Supplementary Fig. 8a) .
We also analysed correlations between IL-1R1 and the markers of differentiation status that we had observed. In an analysis of 818 tumour tissue samples from patients with invasive breast carcinoma, IL-1R1 expression was positively correlated with ZEB1 expression [44] [45] [46] (Fig. 8f) .
Discussion
The present work demonstrates that MIC plasticity determines metastatic success and agrees with a clinical report that mesenchymal markers are downregulated in metastases relative to matched primary tumours 47 . An important implication of our study is that therapies designed to prevent disseminated MIC differentiation compromise their ability to form lethal metastases. Another distinction of our work is that MICs are specifically susceptible to growth inhibition. Interestingly, a recent report indicated that breast carcinomas enriched for mesenchymal markers, similar to our MICs, give rise to immunosuppressive tumours, unlike their more epithelial counterparts 48 . However, we did not specifically examine hallmarks of immunosuppression, as the MIC-suppressive cascade occurred in a T cell-independent manner.
It is becoming increasingly clear that modulating innate immunity must be included in efforts to improve patient outcomes 13, 27, [49] [50] [51] . Tumour-associated lung neutrophils that suppressed MIC colonization in our study appear to be entrained differently to that of metastasis-promoting neutrophils that have been reported in the circulation 13 and of pre-metastatic lungs 11 in other models. At first glance, the neutrophils in our study may seem antimetastatic (they prevented MIC colonization) but at the same time, they may also be considered pro-metastatic (they fortified the MIC potential to generate lethal metastases and did not limit primary tumour growth).
Inflammatory processes that initiate primary disease and drive EMT in primary breast cancers, thus causing MICs to disseminate, are not necessarily productive for MIC colonization. For example, IL-1β aids the growth of some primary tumours 33, 52 and facilitates invasion and extravasation in early stages of metastasis 53 , findings that are consistent with the idea that IL-1β promotes the EMT 17 . However, by specifically examining the role of IL-1β after MIC dissemination, we learned that sustained IL-1β -mediated inflammation or MIC IL-1R signalling prevents colonization and must be shut down for secondary tumour formation. We therefore consider that IL-1β has both dissemination-supportive and colonizationsuppressive functions. These findings are consistent with a recent study showing that IL-1R inhibition, in combination with paclitaxel, moderately reduced primary breast tumour growth but significantly increased metastasis 54 . Identifying the appropriate setting to inhibit inflammation is also necessary. For example, a recent study demonstrated that neoadjuvant inhibition of inflammation (achieved by CCL2 blockade) resulted in significantly enhanced mammary carcinoma lung metastasis 55 . Such spatial and temporal considerations seem crucial, as phase I clinical trials using IL-1R blockade for metastatic disease are being initiated, predominantly supported by preclinical studies demonstrating primary tumour inhibition 56 . Our findings indicate that clinical success of IL-1R inhibition rests upon understanding its role at various stages of disease progression. Hence, IL-1R inhibition therapy may not always confer beneficial effects, and further research is required in order to identify appropriate contexts for administering such therapy.
The evolving paradigm of systemic instigation [57] [58] [59] [60] [61] or inhibition of breast cancer metastasis suggests new directions from which to investigate the interactions between primary tumours and systemic environment during metastatic progression. The fact that inflammatory hallmarks resolved primary tumours that inhibited secondary disease from those that did not, suggests that using primary tumour tissue to better predict metastatic behaviour may enable more accurate identification of patients with a high likelihood of relapse. It is therefore reasonable to think that a primary tumour expressing pro-inflammatory cytokines resulting in activation of an IL-1β -dependent innate immune response in the metastatic niche might keep secondary disease at bay and conversely, that primary tumour removal might prompt recurrence. Such concepts are underscored by our clinical finding that among patients with breast cancer and LN + disease, those whose primary tumour expressed high IL-1β had improved outcomes relative to those with low IL-1β expression. Moreover, IL-1R1 was associated with the expression of mesenchymal factors in our study and in a report on patient circulating tumour cells 62 . The implications of our findings for other cancers 26 and for patients whose disease mimics the biology we have discovered here remain to be determined. 
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Cell lines and general reagents. HMLER, HMLER2 and hMIC were derived from HMECs originally obtained from ATCC. Cell lines were maintained as previously described 21 . MDA-MB-231 human breast epithelial tumour cells were originally obtained from ATCC and maintained in DMEM containing 10% fetal bovine serum (FBS), and their identity was verified by short tandem repeat analysis (Molecular Diagnostics Laboratory at Dana-Farber Cancer Institute). Met1 murine mammary carcinoma cells were a gift from J. Joyce, with permission from A. Borowsky, and maintained as previously described 18 . Their murine strain of origin was confirmed by short tandem repeat analysis (Bioassay Methods Group, NIST). MT2 and MT3-Met1 derived clones were obtained by expansion of plated 0.5 cells per well 20 . All cell lines were routinely tested to confirm the absence of mycoplasma contamination. The following reagents were used: recombinant human IL-1α and IL-1β (R&D Systems); IL-1Ra (CYT-203; ProSpec); BD Matrigel Basement Membrane Matrix (CB40230; BD Biosciences), dox-inducible lentiviral ZEB1-IRES-GFP construct (pTK380).
Animal experiments. Female FVB mice 7 weeks of age and NCR-Nu (nude) mice 6-8 weeks of age were purchased from Taconic Biosciences. Female NOD/SCID mice were bred in-house. Mice were 8-9 weeks of age at the time of injections. Tumour digests. Tumours were chopped into small pieces in sterile conditions then incubated at 37 °C for 4 h in DME containing collagenase A and hyaluronidase. Following digestion, tumour cell suspensions were pelleted, the DME removed and then resuspended in 0.15% trypsin for 3 min. Trypsin was quenched with 10% IFS in DME. Cells were spun down then analysed by flow cytometry or stored in freezing medium (10% DMSO, 90% calf serum).
Lung metastasis quantification. Pulmonary metastases were scored blindly using two methods. First, visible metastases were counted on whole lung tissue under a dissecting microscope. Second, lesions were counted on haematoxylin and eosin (H&E)-stained tissue sections under high power on a Nikon Eclipse 90i microscope.
Neutrophil depletion. Mice were injected intraperitoneally with 12.5, 50 or 100 μ g per 20 g body weight of rat anti-mouse Ly6G antibody (clone 1A8, BioXCell) or rat IgG2a (BioXCell) every other day until indicated experimental end points. The efficiency of neutrophil depletion in blood and lungs was assessed by flow cytometry.
RNA extraction for RNA-seq. Approximately 20-mg samples of lung tissue were excised and immediately snap frozen in liquid nitrogen. Frozen samples were incubated with 600 μ l of lysis buffer (RNeasey Plus Mini Kit, Qiagen) and 20 U of RNAse inhibitors per sample (Applied Biosystems), and immediately disrupted and homogenized with a rotor-stator homogenizer. RNA was extracted using the RNeasey Plus Mini Kit, according to the manufacturer's instructions. Final RNA was resuspended in 50 μ l of RNase-free water and 20 U of RNAse inhibitors per sample.
Library preparation and RNA-seq. Purified total RNA samples were evaluated for quality using an Agilent Bioanalyzer to calculate the RNA integrity number (RIN) score and percentage of RNA fragments > 200 nucleotides (DV 200 ). RNA samples with a RIN score > 7 as well as RNA samples with a RIN score < 7 but DV 200 score > 50% were fragmented at 94 °C for 8 min according to the manufacturer's recommendation. RNA samples with a RIN score < 7 and DV 200 score < 50% were not fragmented and reverse transcription (RT) primers were annealed at 65 °C for 1 min. Libraries were prepared using Roche Kapa Biosystems RiboErase and RNA HyperPrep sample preparation kits from 100 ng of RNA. The finished dsDNA libraries were quantified using a Qubit fluorometer, a Agilent TapeStation 2200 and by RT-qPCR using the Roche Kapa Biosystems library quantification kit according to manufacturer's protocols. Uniquely indexed libraries were pooled in equimolar ratios and sequenced on an Illumina NextSeq500 with single-end 75 bp reads by the Dana-Farber Cancer Institute Molecular Biology Core Facilities.
RNA-seq differential expression and functional enrichment analysis. All samples were processed and analysed using an RNA-seq pipeline implemented in the bcbio-nextgen project (https://bcbio-nextgen.readthedocs.org/en/latest/) and the bcbioRNASeq R package (https://github.com/hbc/bcbioRNASeq) 63 . Reads were aligned to the Genome Reference Consortium Mouse Reference build number 38 (GRCm38) of the mouse genome (aka mm10) augmented with transcript information from Ensembl using STAR 64 with soft trimming enabled to remove adapter sequences, other contaminant sequences such as poly-A tails and low Phred quality score sequences. Counts of reads aligning to known genes were generated by featureCounts 65 for use in quality control measures. In parallel, transcripts per million measurements per isoform were generated by quasialignment using Salmon 66 for use in clustering and differential expression analyses. STAR alignments were checked for evenness of coverage, ribosomal RNA content, genomic context of alignments (for example, alignments to exons and introns), complexity and other quality checks using a combination of FastQC, Qualimap 67 , MultiQC (https://github.com/ewels/MultiQC) and custom tools. Samples were clustered in an unsupervised manner by both principal component analysis and hierarchical means using rlog transformed reads to identify potential outliers and technical artefacts. Outlier samples with low mapping rates (< 70%) or low RIN values and 5'> 3' biases were removed from the analysis. Only data for Ensembl annotated protein coding and long intergenic noncoding RNA genes were retained for further analysis. Differential expression at the gene level was called with DESeq2 68 , using the counts per gene estimated from the Salmon quasialignments by tximport 69 as quantitating at the isoform level has been shown to produce more accurate results at the gene level. Lists of DEGs were examined for GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) term enrichment with clusterProfiler 70 . In addition, cut-off-free gene set enrichment analyses (GSEA) were performed with clusterProfiler, the fast GSEA pre-ranked algorithm 71 and the fold change calculations from DESeq2. Functional gene sets were considered enriched if their false discovery rate-adjusted P value was less than 0.05.
RNA-seq cell signature analysis. For the Coffelt signature 13 , DEGs from their KEP versus wild-type analysis were selected and subset to those with a P value < 0.1. Genes were split into two sets of signature genes: those upregulated in KEP neutrophils and those downregulated. For each signature's genes, the geometric means of expression were determined for samples within our dataset (using data from the transcripts per million count matrix) and the ratio of these values determined. Significance was assessed by simple t-test. Samples with RIN values < 3 were removed from the analysis.
RNA extraction and RT-qPCR. Fresh tumours (up to 150 mg) were homogenized in 1 ml of TRIzol (Ambion, Life Technologies, catalogue no. 15596018) with a tissue homogenizer in a 5-ml BD Falcon polypropylene tube. Cultured cells were collected using a cell lifter (Costar cell lifter, polyethylene, catalogue no. 3008) in 1 ml of TRIzol. Samples were incubated in TRIzol for 5 min at room temperature. Chloroform (0.2 ml; Sigma, catalogue no. 366927) was added to homogenates and the samples were shaken vigorously for 15 s. Samples were incubated at room temperature for 3 min and centrifuged at 13,000 × g for 15 min at 4 °C. The aqueous phase was carefully removed and applied to a genomic DNA elimination column (approximately 350 µ l) (Qiagen RNeasy Plus kit, catalogue no. 74136). The column was centrifuged for 30 s at 13,000 × g. An equal volume of 100% RNA-free ethanol was added to the RNA in the collection tube and mixed with a pipette tip. The sample (700 µ l) was loaded onto an RNeasy column (Qiagen RNeasy Plus kit, catalogue no. 74136) seated in a collection tube and centrifuged for 30 s at 8,000 × g. Columns were washed with Buffer RW1 (700 µ l), then centrifuged for 30 s at 8,000 × g, then washed and centrifuged with buffer RPE (500 µ l) two times. To eliminate the remaining buffer, columns were centrifuged again for 1 min at 8,000 × g. The column was transferred into a new 1.5-ml collection tube and 50 µ l of RNase-free water was pipetted directly onto the column membrane. The sample was incubated for 2 min at room temperature and centrifuged for 1 min at 8,000 × g to elute RNA. The RNA concentration was measured using a Nanodrop (Thermo Scientific). RNA was stored at -80 °C. The miScript II RT kit (Qiagen, catalogue no. 218161) was used to synthesize complementary DNA from total RNA. Therefore, a 20-µ l reaction was prepared containing 4 µ l of 5× miScript Hiflex buffer, 2 µ l of 10× miScript Nucleics mix, 2 µ l Reverse Transcriptase mix and 1 µ g of purified RNA in 12 µ l of RNase-free water. According to the manufacturer's protocol, the samples were amplified using a Biorad Mycycler at 37 °C for 60 min, 95 °C for 5 min and cooled to 4 °C. RNase-free water (80 µ l) was added to each cDNA sample (20 µ l) to obtain a concentration of 10-15 ng µ l -1
. cDNA was stored at -20 °C. Relative gene expression was determined using a QuantiFast SYBR Green PCR kit (Qiagen) and Quantitect Primer Assays (Qiagen). qPCR amplifications were carried out in 384-well plates using a Lightcycler 480 (Roche). The following human-specific 1 nature research | reporting summary 
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Data analysis
Prism, NIH ImageJ (http://imagej.nih.gov/ij/), FlowJo, CellProfiler, GOBO database (http://co.bmc.lu.se/gobo/gsa.pl), and cBioPortal database (http://www.cbioportal.org/index.do). All the information related to software and codes used for RNAseq analysis are available on DOI (https://doi.org/10.5281/zenodo.1172004).
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Sample size
Sample sizes were chosen based on previous experience with the models and methods used in this study. Online Methods -Animals
Data exclusions No data were excluded from analysis
Online Methods -Statistical Analysis.
Replication
Biological experiments were repeated at least twice whenever possible. In vitro experiments were run with at least 2 biological replicates and 3 technical replicates. All attempts at replication were successful. Online Methods -Statistical Analysis.
Randomization Animals were randomly assigned to groups. 
